Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SELECT-SLE phase 3 study of upadacitinib in moderate to severe active systemic lupus erythematosus
CTR20232960Phase 3Active
- Sponsor
- AbbVie Inc.
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of upadacitinib in systemic lupus erythematosus (SLE), sponsored by AbbVie Inc.. Started Apr 2024; status: active.
02
Drugs
upadacitinib
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on CTR20232960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232960.